Octreotide Sun

Octreotide, the active ingredient in Octreotide Sun, is a somatostatin analog presented as an injectable formulation for intravenous and subcutaneous use. It helps regulate excessive hormone secretion associated with neuroendocrine tumors, acromegaly, and severe diarrhea caused by vasoactive intestinal peptide, providing symptom control in adult patients.

GNH USA supplies Octreotide Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Octreotide is a somatostatin analog used to manage conditions involving excess hormone secretion. - Acromegaly: reduces growth hormone and IGF‑1 levels, controlling disease activity. - Carcinoid syndrome: decreases flushing and diarrhea by inhibiting serotonin release. - VIPoma: controls watery diarrhea and electrolyte loss through suppression of vasoactive intestinal peptide. - Post‑operative pancreatic fistula: lowers pancreatic secretions, aiding fistula closure.

Octreotide may cause a range of adverse reactions, most of which are mild and reversible. Common Side Effects: - Injection site pain or erythema - Nausea or vomiting - Abdominal cramps or discomfort - Diarrhea - Hyperglycemia or altered glucose tolerance - Gallbladder sludge or biliary colic Serious or Rare Side Effects: - Acute pancreatitis - Severe hyperglycemia requiring insulin - Cardiac arrhythmias or bradycardia - Hypotension or circulatory collapse - Anaphylactic or severe allergic reactions - Hepatic dysfunction

When prescribing Octreotide, several safety considerations should be observed. - Glucose monitoring: assess blood sugar regularly as hyperglycemia may occur. - Gallbladder assessment: evaluate for gallstones before long‑term therapy. - Renal/hepatic function: adjust dosing in patients with significant impairment. - Pregnancy: avoid unless benefit outweighs potential risk to the fetus. - Hypersensitivity: discontinue if signs of allergic reaction develop. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide can interact with other medicines, affecting their efficacy or safety. Major Interactions (Avoid): - Cyclosporine: octreotide may increase cyclosporine levels, raising toxicity risk. - Oral contraceptives: reduced absorption may diminish contraceptive effectiveness. - Insulin or oral hypoglycemics: enhanced glucose‑lowering effect may require dose adjustment. - Quinidine: increased quinidine concentrations can lead to cardiac toxicity. - Other somatostatin analogs: additive hormonal suppression may cause severe side effects. Moderate Interactions (Monitor Closely): - Dopamine agonists: combined effect on prolactin may require monitoring. - Antidepressants affecting serotonin: potential for altered serotonin levels. - Gastro‑intestinal motility agents: overlapping effects on gut motility may need observation.